Valuation: Moderna, Inc.

Market Cap 31.65B 27.67B 25.43B 23.7B 44.95B 3,013B 45.63B 305B 119B 1,481B 119B 116B 5,104B P/E 2026 *
-9.24x
P/E 2027 * -17x
Enterprise Value 28.04B 24.51B 22.53B 21B 39.83B 2,670B 40.43B 270B 105B 1,312B 105B 103B 4,523B EV / Sales 2026 *
13.4x
EV / Sales 2027 * 11.6x
Free-Float
92.69%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Moderna, Inc.

1 day+10.01%
1 week+33.49%
Current month+13.89%
1 month+74.76%
3 months+62.11%
6 months+158.46%
Current year+170.46%
1 week 66.3
Extreme 66.3
81.4
1 month 45.4
Extreme 45.4
81.4
Current year 29.81
Extreme 29.81
81.4
1 year 22.28
Extreme 22.28
81.4
3 years 22.28
Extreme 22.28
170.47
5 years 22.28
Extreme 22.28
497.49
10 years 11.54
Extreme 11.54
497.49
Manager TitleAgeSince
Chief Executive Officer 54 01/03/2011
Director of Finance/CFO 49 06/09/2022
President 50 01/11/2024
Director TitleAgeSince
Chairman 63 01/02/2012
Director/Board Member 54 01/03/2011
Director/Board Member 69 11/12/2019
Date Insider Type Main position Quantity % Market Cap.
06-15Fiscal year

Chairperson

160,008 0.0403%
06-05Fiscal year

Chief Financial Officer

29,301 0.0074%
06-05Fiscal year

General Counsel

29,301 0.0074%
Change 5-day change 1-year change 3-year change Capi.($)
-1.99%+33.49%+163.41%-34.35% 31.65B
+4.73%+5.50%+19.45%-8.94% 66.56B
-1.93%+0.54%+58.86%+226.84% 57.64B
+1.07%+42.10%+42.10%+42.10% 42.24B
+3.45%+3.54%-49.20%-56.09% 39.09B
-4.05%+7.01%+62.26%-24.13% 31.91B
-0.28%+8.68%+71.42%+87.73% 23.35B
+2.87%+15.37%+10.72%+196.62% 18.92B
-0.13%+2.79%+67.55%+130.16% 17.17B
-1.53%+10.76%+80.22%+348.78% 15.12B
Average +2.95%+5.85%+52.68%+90.87% 34.37B
Weighted average by Cap. +2.84%+4.55%+46.40%+68.34%

Financials

2026 *2027 *
Net sales 2.09B 1.83B 1.68B 1.57B 2.97B 199B 3.02B 20.19B 7.85B 97.95B 7.86B 7.69B 338B 2.53B 2.21B 2.03B 1.89B 3.59B 241B 3.65B 24.39B 9.48B 118B 9.49B 9.29B 408B
Net income -3.4B -2.97B -2.73B -2.54B -4.83B -323B -4.9B -32.77B -12.74B -159B -12.75B -12.48B -548B -1.82B -1.6B -1.47B -1.37B -2.59B -174B -2.63B -17.6B -6.84B -85.4B -6.85B -6.7B -294B
Net Debt -3.61B -3.15B -2.9B -2.7B -5.12B -343B -5.2B -34.78B -13.52B -169B -13.54B -13.24B -582B -2.27B -1.99B -1.83B -1.7B -3.23B -217B -3.28B -21.94B -8.53B -106B -8.54B -8.36B -367B
Logo Moderna, Inc.
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (96.1%); - revenue from collaboration agreements (1.5%); - revenue from royalties and licensing (1.3%); - revenue from grants (1.1%). At the end of 2024, the group's portfolio comprises 37 products in clinical development, of which 10 in phase I, 18 in phase II and 9 in phase III, 3 products in preclinical development, and 4 products in commercial phase. Net sales are distributed geographically as follows: the United States (55.1%), Europe (18.5%) and other (26.4%).
Employees
4,700
Date Price Change Volume
02/07/26 $79.76 +10.01% 14,111,998
01/07/26 $72.50 +3.53% 9,275,292
30/06/26 $70.03 +0.47% 11,805,910
29/06/26 $69.70 +3.61% 8,077,421
26/06/26 $67.27 +12.59% 14,456,655
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
24
Last Close Price
79.76USD
Average target price
45.85USD
Spread / Average Target
-42.52%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MRNA Stock